,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,71206,1057,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,71206,1057,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,71206,1057,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,71206,1057,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,71206,1057,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,71206,1057,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,421,1,3,,17388747,1057,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
7,426,1,2,,17388747,1057,Inconclusive,,,,,Cell Viability - Jurkat,Confirmatory,,
8,427,1,1,,17388747,1057,Inconclusive,,,,,Cell Viability - Hek293,Confirmatory,,
9,433,1,1,,17388747,1057,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
10,434,1,2,,17388747,1057,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
11,435,1,2,,17388747,1057,Inconclusive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
12,445,3,1,,17388747,1057,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,530,1,1,,17388747,1057,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
14,540,1,1,,17388747,1057,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
15,541,1,1,,17388747,1057,Inconclusive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
16,542,1,1,,17388747,1057,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
17,543,1,1,,17388747,1057,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
18,544,2,1,,17388747,1057,Inconclusive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
19,545,1,1,,17388747,1057,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
20,546,1,1,,17388747,1057,Inconclusive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
21,584,1,3,,17388747,1057,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
22,585,1,4,,17388747,1057,Inconclusive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
23,595,1,3,,17388747,1057,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
24,596,1,2,,17388747,1057,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
25,603,1,2,,17388747,1057,Active,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
26,605,1,2,,17388747,1057,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
27,654,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
28,655,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
29,656,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
30,657,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
31,658,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
32,659,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
33,660,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
34,661,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
35,662,1,1,,17388747,1057,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
36,663,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
37,664,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
38,665,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
39,666,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
40,667,1,1,,17388747,1057,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
41,875,1,2,,17388747,1057,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
42,880,2,1,,17388747,1057,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
43,880,2,1,,17388747,1057,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
44,881,2,2,,17388747,1057,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
45,884,1,2,,17388747,1057,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
46,885,1,2,,17388747,1057,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
47,886,1,2,,17388747,1057,Active,122921310.0,,0.631,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
48,886,1,2,,17388747,1057,Active,122921311.0,,0.631,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
49,887,1,2,,17388747,1057,Active,1832253.0,246.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
50,889,1,3,,17388747,1057,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
51,892,1,2,,17388747,1057,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
52,893,1,2,,17388747,1057,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
53,893,1,2,,17388747,1057,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
54,894,2,1,,17388747,1057,Active,31542939.0,3248.0,10.0,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
55,900,1,3,,17388747,1057,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
56,902,1,2,,17388747,1057,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
57,912,1,2,,17388747,1057,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
58,921,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
59,923,1,2,,17388747,1057,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
60,924,1,2,,17388747,1057,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
61,925,1,2,,17388747,1057,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
62,926,1,2,,17388747,1057,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
63,938,1,2,,17388747,1057,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
64,946,1,2,,17388747,1057,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
65,947,1,2,,17388747,1057,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
66,948,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
67,955,1,2,,17388747,1057,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
68,960,1,2,,17388747,1057,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
69,961,1,2,,17388747,1057,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
70,962,1,2,,17388747,1057,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
71,963,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
72,964,1,2,,17388747,1057,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
73,965,1,2,,17388747,1057,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-003,Confirmatory,,
74,966,1,2,,17388747,1057,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-004,Confirmatory,,
75,967,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
76,968,1,2,,17388747,1057,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-009,Confirmatory,,
77,969,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
78,970,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
79,971,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
80,972,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
81,973,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
82,974,1,2,,17388747,1057,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-021,Confirmatory,,
83,975,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
84,976,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
85,977,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
86,978,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
87,979,1,2,,17388747,1057,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-007,Confirmatory,,
88,980,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
89,981,1,2,,17388747,1057,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-010,Confirmatory,,
90,982,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
91,983,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
92,984,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
93,985,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
94,986,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
95,987,1,2,,17388747,1057,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-022,Confirmatory,,
96,988,1,2,,17388747,1057,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-024,Confirmatory,,
97,989,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
98,993,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
99,994,1,2,,17388747,1057,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
100,995,1,2,,17388747,1057,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
101,1030,2,1,,17388747,1057,Active,30582681.0,216.0,1.4989,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
102,1376,1,2,,47193686,1057,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
103,1385,2,2,,47193686,1057,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
104,1422,1,1,,47193686,1057,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
105,1452,1,1,,17388747,1057,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
106,1457,1,1,,17388747,1057,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
107,1458,1,1,,17388747,1057,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
108,1465,1,1,,47193686,1057,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
109,1469,1,1,,17388747,1057,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
110,1471,2,1,,17388747,1057,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
111,1476,2,1,,17388747,1057,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
112,1478,2,1,,17388747,1057,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
113,1479,1,2,,17388747,1057,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
114,1487,1,1,,17388747,1057,Inconclusive,27436948.0,4000.0,14.1254,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
115,1490,2,1,,17388747,1057,Active,10954339.0,,39.8107,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
116,1529,1,1,,47193686,1057,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
117,1530,1,1,,47193686,1057,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
118,1531,1,1,,47193686,1057,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
119,1532,1,1,,47193686,1057,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
120,1621,1,2,,47193686,1057,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
121,1626,1,2,,47193686,1057,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
122,1688,1,1,,17388747,1057,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
123,1766,1,1,,17388747,1057,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
124,1766,1,1,,17388747,1057,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
125,1768,1,1,,17388747,1057,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
126,1768,1,1,,17388747,1057,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
127,1850,2,1,,47193686,1057,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
128,1863,2,1,,47193686,1057,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
129,1899,1,3,,47193686,1057,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
130,1903,2,3,,47193686,1057,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
131,1906,1,3,,47193686,1057,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
132,1947,1,2,,47193686,1057,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
133,1948,1,1,,17388747,1057,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
134,1950,1,3,,47193686,1057,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
135,1956,1,1,,47193686,1057,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
136,1962,1,2,,47193686,1057,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
137,1974,1,2,,47193686,1057,Active,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
138,1987,1,2,,47193686,1057,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
139,2016,1,3,,47193686,1057,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
140,2023,1,3,,47193686,1057,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
141,2025,1,3,,47193686,1057,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
142,2029,1,3,,47193686,1057,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
143,2052,2,1,,47193686,1057,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
144,2057,1,2,,47193686,1057,Active,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
145,2066,1,4,,47193686,1057,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
146,2101,1,1,,17388747,1057,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
147,2107,1,1,,17388747,1057,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
148,2112,1,1,,17388747,1057,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
149,2120,1,1,,17388747,1057,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
150,2129,1,2,,47193686,1057,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
151,2130,1,3,,47193686,1057,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
152,2166,1,2,,47193686,1057,Inactive,20336335.0,598.0,,,"Counterscreen for MCL1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
153,2168,1,2,,47193686,1057,Active,78070770.0,4170.0,,,Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
154,2174,1,3,,47193686,1057,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
155,2176,1,2,,47193686,1057,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
156,2177,1,3,,47193686,1057,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
157,2234,1,2,,47193686,1057,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
158,2235,1,2,,47193686,1057,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
159,2280,2,3,,47193686,1057,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
160,2300,1,3,,47193686,1057,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
161,2380,1,2,,47193686,1057,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
162,2435,1,2,,47193686,1057,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
163,2445,1,2,,47193686,1057,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
164,2462,1,1,,47193686,1057,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
165,2462,1,1,,47193686,1057,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
166,2517,2,1,,17388747,1057,Active,6980812.0,,1.2589,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
167,2520,1,4,,47193686,1057,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
168,2521,1,3,,47193686,1057,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
169,2524,1,2,,47193686,1057,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
170,2528,1,2,,17388747,1057,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
171,2540,1,2,,47193686,1057,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
172,2544,1,2,,47193686,1057,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
173,2546,1,1,,17388747,1057,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
174,2549,1,1,,17388747,1057,Active,282403581.0,,6.3096,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
175,2551,1,1,,17388747,1057,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
176,2557,1,3,,47193686,1057,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
177,2599,1,2,,47193686,1057,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
178,2606,1,2,,47193686,1057,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
179,2629,1,1,,47193686,1057,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
180,2650,2,1,,47193686,1057,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
181,2661,1,1,,47193686,1057,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
182,2662,2,1,,17388747,1057,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
183,2690,1,2,,47193686,1057,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
184,2716,1,1,,47193686,1057,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
185,2717,1,2,,47193686,1057,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
186,2718,1,1,,47193686,1057,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
187,2751,2,2,,47193686,1057,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
188,2796,1,4,,47193686,1057,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
189,2797,1,2,,47193686,1057,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
190,2805,2,2,,47193686,1057,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
191,2806,2,2,,47193686,1057,Active,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
192,2825,1,2,,47193686,1057,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
193,19630,3,3,,103275455,1057,Unspecified,,,,,Partition coefficient (logP),Other,9371243.0,
194,85482,6,2,,103275455,1057,Unspecified,,,5.0,IC50,Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line),Confirmatory,9371243.0,
195,158873,8,1,,103275455,1057,Active,,,5.66,IC50,In vitro antimalarial activity against Plasmodium falciparum,Confirmatory,7608896.0,
196,160507,6,7,,103275455,1057,Active,75066909.0,,4.0,IC50,5-LO inhibitory activity was determined by inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes (PMNL),Confirmatory,9371243.0,
197,231071,3,4,,103275455,1057,Unspecified,,,,,Peroxidant property was expressed as ratio of uMol of malondialdehyde and mMol of deoxyribose released by 75 uM test compound,Other,9371243.0,
198,233179,5,1,,103275455,1057,Unspecified,,,,,"Antioxidant potential was assessed from reducing activity against 2,2,di-phenyl-1-picrylhydrazyl.",Other,9371243.0,
199,280290,3,9,,103275455,1057,Unspecified,126180.0,6401.0,,,Inhibition of human E-selectin after 2 hrs at 100 uM,Other,17302397.0,
200,280292,4,8,,103275455,1057,Unspecified,215274139.0,6403.0,,,Inhibition of human P-selectin after 2 hrs at 100 uM,Other,17302397.0,
201,280294,3,11,,103275455,1057,Unspecified,126178.0,6402.0,,,Inhibition of human L-selectin after 2 hrs at 100 uM,Other,17302397.0,
202,280295,5,4,,103275455,1057,Unspecified,,,,,Inhibition of attachment of HL60 cells to E-selectin at 109 uM after 5 mins,Other,17302397.0,
203,280296,5,5,,103275455,1057,Unspecified,,,,,Inhibition of attachment of HL60 cells to P-selectin at 109 uM after 5 mins,Other,17302397.0,
204,283976,6,2,,103275455,1057,Active,,,0.99,EC50,Antibacterial activity against Staphylococcus epidermidis,Confirmatory,17035037.0,
205,283977,6,2,,103275455,1057,Active,,,0.49,EC50,Antibacterial activity against Staphylococcus aureus,Confirmatory,17035037.0,
206,314588,7,6,,103275455,1057,Active,21431789.0,,2.0,IC50,Antagonist activity at LuxP receptor in Vibrio harveyi MM32 assessed as inhibition of autoinducer-2-mediated quorum sensing after 3 to 4 hrs,Confirmatory,18262415.0,
207,314589,3,3,,103275455,1057,Unspecified,,,,,Growth inhibition of Vibrio harveyi assessed as time required to double bacterial growth at 20 uM,Other,18262415.0,
208,320784,9,5,,103275455,1057,Unspecified,1351132.0,497756.0,500.0,IC50,Inhibition of rat intestinal sucrase,Confirmatory,18039578.0,
209,320790,3,10,,103275455,1057,Unspecified,1351132.0,497756.0,,,Inhibition of rat intestinal sucrase at 500 uM,Other,18039578.0,
210,335901,6,3,,103275455,1057,Active,,,37.8,IC50,Antioxidant activity assessed as DPPH free radical scavenging activity after 30 mins,Confirmatory,12350144.0,
211,336478,3,7,,103275455,1057,Unspecified,,,,,Inhibition of COX2 at 100 uM by scintillation proximity assay,Other,12444669.0,
212,336481,3,7,,103275455,1057,Inactive,,,,,Inhibition of COX2 at 10 uM by scintillation proximity assay,Other,12444669.0,
213,377909,6,3,,103275455,1057,Active,,,4.2,EC50,Antioxidant activity assessed as DPPH free radical scavenging activity,Confirmatory,11076575.0,
214,403340,11,1,,103275455,1057,Unspecified,,,144.0,IC50,Inhibition of COX2,Confirmatory,16038536.0,
215,417959,6,2,,103275455,1057,Unspecified,,,,,Antifungal activity against Candida albicans after 48 hrs by broth microdilution technique,Other,19232493.0,
216,417960,6,2,,103275455,1057,Unspecified,,,,,Antifungal activity against Candida tropicalis after 48 hrs by broth microdilution technique,Other,19232493.0,
217,417961,6,2,,103275455,1057,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae after 48 hrs by broth microdilution technique,Other,19232493.0,
218,417962,6,2,,103275455,1057,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans after 48 hrs by broth microdilution technique,Other,19232493.0,
219,417963,6,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Aspergillus fumigatus after 48 hrs by broth microdilution technique,Other,19232493.0,
220,417964,6,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Aspergillus flavus after 48 hrs by broth microdilution technique,Other,19232493.0,
221,417965,6,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Aspergillus niger after 48 hrs by broth microdilution technique,Other,19232493.0,
222,417966,6,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Microsporum gypseum after 48 hrs by broth microdilution technique,Other,19232493.0,
223,417967,7,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Epidermophyton floccosum after 48 hrs by broth microdilution technique,Other,19232493.0,
224,417968,6,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Trichophyton rubrum after 48 hrs by broth microdilution technique,Other,19232493.0,
225,417969,6,2,,103275455,1057,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes after 48 hrs by broth microdilution technique,Other,19232493.0,
226,434955,1,2,,47193686,1057,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
227,434962,1,2,,47193686,1057,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
228,434970,1,2,,47193686,1057,Inactive,124487323.0,76768.0,,,Single concentration confirmation of uHTS hits from a small molecule activators of mouse intestinal alkaline phosphatase via a luminescent assay,Screening,,
229,434971,1,2,,47193686,1057,Active,124487323.0,76768.0,,,Single concentration confirmation of uHTS hits from a small molecule inhibitors of mouse intestinal alkaline phosphatase via a luminescent assay,Screening,,
230,434973,1,3,,47193686,1057,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
231,434989,1,1,,47193686,1057,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
232,435003,1,3,,47193686,1057,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
233,435005,1,1,,47193686,1057,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
234,435022,2,2,,47193686,1057,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
235,435030,1,2,,47193686,1057,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
236,435030,1,2,,47193686,1057,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
237,449728,1,2,,47193686,1057,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
238,449739,1,2,,47193686,1057,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
239,449762,1,2,,47193686,1057,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
240,449763,1,3,,47193686,1057,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
241,449768,1,1,,47193686,1057,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
242,463079,1,2,,47193686,1057,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
243,463082,1,1,,47193686,1057,Active,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
244,463104,1,2,,47193686,1057,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
245,463141,1,2,,47193686,1057,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
246,463190,1,2,,47193686,1057,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
247,463195,1,2,,47193686,1057,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
248,463210,1,2,,47193686,1057,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
249,463212,1,1,,47193686,1057,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
250,485270,1,1,,47193686,1057,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
251,485272,1,1,,47193686,1057,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
252,485273,2,1,,47193686,1057,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
253,485275,1,3,,47193686,1057,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
254,485290,1,1,,17388747,1057,Inconclusive,20150581.0,,0.0865,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
255,485317,1,2,,47193686,1057,Active,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
256,485346,1,1,,47193686,1057,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
257,485346,1,1,,47193686,1057,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
258,488847,1,3,,47193686,1057,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
259,488890,1,2,,47193686,1057,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
260,488975,1,2,,47193686,1057,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
261,488977,1,2,,47193686,1057,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
262,489030,2,1,,47193686,1057,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
263,489031,2,1,,47193686,1057,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
264,492140,3,3,,103275455,1057,Unspecified,,,,,Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay,Other,20565070.0,
265,492404,3,9,,103275455,1057,Active,113576.0,213.0,,,Binding affinity to human serum albumin in 100 mM phosphate buffer at pH 7.4 assessed as formation of biotin-LC-hydrazide labeled protein carbonyls at 100 uM pretreated 60 mins before biotin-LC-hydrazide challenge measured after 60 mins by SDS-PAGE/Western blotting,Other,20598557.0,
266,492961,1,1,,17388747,1057,Inconclusive,72386991.0,3656265.0,7.9433,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
267,493011,1,1,,47193686,1057,Active,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
268,493012,1,1,,47193686,1057,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
269,493036,1,2,,47193686,1057,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
270,493151,1,2,,47193686,1057,Active,21955158.0,200315.0,,,Single concentration confirmation of uHTS for APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
271,504327,1,1,,17388747,1057,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
272,504332,1,1,,17388747,1057,Active,168985070.0,,3.5481,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
273,504370,1,1,,17388747,1057,Inactive,13124873.0,865.0,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: ME-1 cellular proliferation,Confirmatory,,
274,504370,1,1,,17388747,1057,Inactive,49574546.0,861.0,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: ME-1 cellular proliferation,Confirmatory,,
275,504374,2,1,,17388747,1057,Active,13124873.0,865.0,3.965,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation,Confirmatory,,
276,504374,2,1,,17388747,1057,Active,49574546.0,861.0,3.965,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation,Confirmatory,,
277,504375,1,2,,17388747,1057,Active,13124873.0,865.0,0.8877,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation with Orthogonal Assay,Confirmatory,,
278,504375,1,2,,17388747,1057,Active,49574546.0,861.0,0.8877,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation with Orthogonal Assay,Confirmatory,,
279,504406,1,1,,47193686,1057,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
280,504749,1,3,,17388747,1057,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
281,504749,1,3,1.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
282,504749,1,3,2.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
283,504749,1,3,3.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
284,504749,1,3,4.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
285,504749,1,3,5.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
286,504749,1,3,6.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
287,504749,1,3,7.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
288,504749,1,3,8.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
289,504749,1,3,9.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
290,504749,1,3,10.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
291,504749,1,3,11.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
292,504749,1,3,12.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
293,504749,1,3,13.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
294,504749,1,3,14.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
295,504749,1,3,15.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
296,504749,1,3,16.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
297,504749,1,3,17.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
298,504749,1,3,18.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
299,504749,1,3,19.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
300,504749,1,3,20.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
301,504749,1,3,21.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
302,504749,1,3,22.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
303,504749,1,3,23.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
304,504749,1,3,24.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
305,504749,1,3,25.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
306,504749,1,3,26.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
307,504749,1,3,27.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
308,504749,1,3,28.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
309,504749,1,3,29.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
310,504749,1,3,30.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
311,504749,1,3,31.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
312,504749,1,3,32.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
313,504749,1,3,33.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
314,504749,1,3,34.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
315,504749,1,3,35.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
316,504749,1,3,36.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
317,504749,1,3,37.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
318,504749,1,3,38.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
319,504749,1,3,39.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
320,504749,1,3,40.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
321,504749,1,3,41.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
322,504749,1,3,42.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
323,504749,1,3,43.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
324,504749,1,3,44.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
325,504749,1,3,45.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
326,504749,1,3,46.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
327,504749,1,3,47.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
328,504749,1,3,48.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
329,504749,1,3,49.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
330,504749,1,3,50.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
331,504749,1,3,51.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
332,504749,1,3,52.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
333,504749,1,3,53.0,17388747,1057,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
334,504749,1,3,54.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
335,504749,1,3,55.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
336,504749,1,3,56.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
337,504749,1,3,57.0,17388747,1057,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
338,504749,1,3,58.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
339,504749,1,3,59.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
340,504749,1,3,60.0,17388747,1057,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
341,504749,1,3,61.0,17388747,1057,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
342,504832,1,1,,17388747,1057,Inconclusive,,,19.0115,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
343,504834,1,1,,17388747,1057,Inconclusive,,,19.0115,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
344,504847,1,1,,17388747,1057,Active,63054845.0,7421.0,79.4328,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
345,504865,1,1,,17388747,1057,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
346,588511,1,2,,47193686,1057,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
347,588513,1,1,,17388747,1057,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
348,588514,1,1,,17388747,1057,Active,348019627.0,2099.0,8.9125,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
349,588515,1,1,,17388747,1057,Inconclusive,124375976.0,367.0,50.1187,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
350,588516,1,1,,17388747,1057,Inconclusive,124375976.0,367.0,50.1187,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
351,588526,1,1,,17388747,1057,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
352,588527,1,1,,17388747,1057,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
353,588532,1,1,,17388747,1057,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
354,588533,1,1,,17388747,1057,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
355,588534,1,1,,17388747,1057,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
356,588535,1,1,,17388747,1057,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
357,588536,1,1,,17388747,1057,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
358,588537,1,1,,17388747,1057,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
359,588541,1,1,,17388747,1057,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
360,588543,1,1,,17388747,1057,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
361,588544,1,1,,17388747,1057,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
362,588545,1,1,,17388747,1057,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
363,588546,1,1,,17388747,1057,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
364,588547,1,1,,17388747,1057,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
365,588579,1,1,,17388747,1057,Active,7705344.0,51426.0,2.9935,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
366,588627,1,1,,47193686,1057,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
367,588675,1,1,,47193686,1057,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
368,588676,1,1,,47193686,1057,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
369,588812,1,1,,17388747,1057,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
370,588812,1,1,1.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
371,588812,1,1,2.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
372,588812,1,1,3.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
373,588812,1,1,4.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
374,588812,1,1,5.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
375,588812,1,1,6.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
376,588812,1,1,7.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
377,588812,1,1,8.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
378,588812,1,1,9.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
379,588812,1,1,10.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
380,588812,1,1,11.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
381,588812,1,1,12.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
382,588812,1,1,13.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
383,588812,1,1,14.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
384,588812,1,1,15.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
385,588812,1,1,16.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
386,588812,1,1,17.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
387,588812,1,1,18.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
388,588812,1,1,19.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
389,588812,1,1,20.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
390,588812,1,1,21.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
391,588812,1,1,22.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
392,588812,1,1,23.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
393,588812,1,1,24.0,17388747,1057,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
394,588812,1,1,25.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
395,588812,1,1,26.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
396,588812,1,1,27.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
397,588812,1,1,28.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
398,588812,1,1,29.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
399,588812,1,1,30.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
400,588812,1,1,31.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
401,588812,1,1,32.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
402,588812,1,1,33.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
403,588812,1,1,34.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
404,588812,1,1,35.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
405,588812,1,1,36.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
406,588812,1,1,37.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
407,588812,1,1,38.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
408,588812,1,1,39.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
409,588812,1,1,40.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
410,588812,1,1,41.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
411,588812,1,1,42.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
412,588812,1,1,43.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
413,588812,1,1,44.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
414,588812,1,1,45.0,17388747,1057,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
415,588812,1,1,46.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
416,588812,1,1,47.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
417,588812,1,1,48.0,17388747,1057,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
418,588812,1,1,49.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
419,588812,1,1,50.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
420,588812,1,1,51.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
421,588812,1,1,52.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
422,588812,1,1,53.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
423,588812,1,1,54.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
424,588812,1,1,55.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
425,588812,1,1,56.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
426,588812,1,1,57.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
427,588812,1,1,58.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
428,588812,1,1,59.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
429,588812,1,1,60.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
430,588812,1,1,61.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
431,588812,1,1,62.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
432,588812,1,1,63.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
433,588812,1,1,64.0,17388747,1057,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
434,588812,1,1,65.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
435,588812,1,1,66.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
436,588812,1,1,67.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
437,588812,1,1,68.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
438,588812,1,1,69.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
439,588812,1,1,70.0,17388747,1057,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
440,588812,1,1,71.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
441,588812,1,1,72.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
442,588812,1,1,73.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
443,588812,1,1,74.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
444,588812,1,1,75.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
445,588812,1,1,76.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
446,588812,1,1,77.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
447,588812,1,1,78.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
448,588812,1,1,79.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
449,588812,1,1,80.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
450,588812,1,1,81.0,17388747,1057,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
451,588813,1,1,,17388747,1057,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
452,588813,1,1,1.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
453,588813,1,1,2.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
454,588813,1,1,3.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
455,588813,1,1,4.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
456,588813,1,1,5.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
457,588813,1,1,6.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
458,588813,1,1,7.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
459,588813,1,1,8.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
460,588813,1,1,9.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
461,588813,1,1,10.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
462,588813,1,1,11.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
463,588813,1,1,12.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
464,588813,1,1,13.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
465,588813,1,1,14.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
466,588813,1,1,15.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
467,588813,1,1,16.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
468,588813,1,1,17.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
469,588813,1,1,18.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
470,588813,1,1,19.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
471,588813,1,1,20.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
472,588813,1,1,21.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
473,588813,1,1,22.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
474,588813,1,1,23.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
475,588813,1,1,24.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
476,588813,1,1,25.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
477,588813,1,1,26.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
478,588813,1,1,27.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
479,588813,1,1,28.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
480,588813,1,1,29.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
481,588813,1,1,30.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
482,588813,1,1,31.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
483,588813,1,1,32.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
484,588813,1,1,33.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
485,588813,1,1,34.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
486,588813,1,1,35.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
487,588813,1,1,36.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
488,588813,1,1,37.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
489,588813,1,1,38.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
490,588813,1,1,39.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
491,588813,1,1,40.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
492,588813,1,1,41.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
493,588813,1,1,42.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
494,588813,1,1,43.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
495,588813,1,1,44.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
496,588813,1,1,45.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
497,588813,1,1,46.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
498,588813,1,1,47.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
499,588813,1,1,48.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
500,588813,1,1,49.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
501,588813,1,1,50.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
502,588813,1,1,51.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
503,588813,1,1,52.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
504,588813,1,1,53.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
505,588813,1,1,54.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
506,588813,1,1,55.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
507,588813,1,1,56.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
508,588813,1,1,57.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
509,588813,1,1,58.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
510,588813,1,1,59.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
511,588813,1,1,60.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
512,588813,1,1,61.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
513,588813,1,1,62.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
514,588813,1,1,63.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
515,588813,1,1,64.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
516,588813,1,1,65.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
517,588813,1,1,66.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
518,588813,1,1,67.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
519,588813,1,1,68.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
520,588813,1,1,69.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
521,588813,1,1,70.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
522,588813,1,1,71.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
523,588813,1,1,72.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
524,588813,1,1,73.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
525,588813,1,1,74.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
526,588813,1,1,75.0,17388747,1057,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
527,588813,1,1,76.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
528,588813,1,1,77.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
529,588813,1,1,78.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
530,588813,1,1,79.0,17388747,1057,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
531,588813,1,1,80.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
532,588813,1,1,81.0,17388747,1057,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
533,588834,2,1,,17388747,1057,Inconclusive,325651834.0,3757.0,2.8184,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
534,588834,2,1,,144204694,1057,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
535,602332,1,1,,17388747,1057,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
536,607494,5,5,,103275455,1057,Active,115449.0,759.0,7.41,Ki,Inhibition of human CA1 using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
537,607495,5,5,,103275455,1057,Active,115456.0,760.0,0.54,Ki,Inhibition of human CA2 using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
538,607496,6,5,,103275455,1057,Active,116241278.0,765.0,0.52,Ki,Inhibition of human CA6 using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
539,607497,6,5,,103275455,1057,Active,123910379.0,,4.39,Ki,Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
540,615280,3,2,,103275455,1057,Active,,,2.0,IC50,Inhibition of quorum sensing regulated bioluminescence in Vibrio harveyi,Confirmatory,20669927.0,
541,624030,1,2,,17388747,1057,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
542,624031,1,2,,17388747,1057,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
543,624032,1,2,,17388747,1057,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
544,624044,1,2,,17388747,1057,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
545,624170,1,1,,17388747,1057,Inconclusive,71051501.0,2744.0,35.4813,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
546,624172,1,1,,17388747,1057,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
547,624173,1,3,,17388747,1057,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
548,624296,1,1,,17388747,1057,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
549,624297,1,1,,17388747,1057,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
550,624606,1,9,,103275455,1057,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
551,624616,1,8,,103275455,1057,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
552,625144,5,5,,103275455,1057,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
553,625145,4,7,,103275455,1057,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
554,625146,5,5,,103275455,1057,Active,126397.0,100009114.0,2.114,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
555,625147,4,7,,103275455,1057,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
556,625148,4,7,,103275455,1057,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
557,625149,4,7,,103275455,1057,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
558,625150,5,5,,103275455,1057,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
559,625151,4,7,,103275455,1057,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
560,625152,4,7,,103275455,1057,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
561,625153,4,7,,103275455,1057,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
562,625154,4,7,,103275455,1057,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
563,625155,4,7,,103275455,1057,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
564,625156,1,9,,103275455,1057,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
565,625157,6,2,,103275455,1057,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
566,625158,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
567,625159,5,5,,103275455,1057,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
568,625160,1,9,,103275455,1057,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
569,625161,4,7,,103275455,1057,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
570,625162,4,7,,103275455,1057,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
571,625163,4,7,,103275455,1057,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
572,625164,1,6,,103275455,1057,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
573,625165,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
574,625166,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
575,625167,5,5,,103275455,1057,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
576,625168,4,7,,103275455,1057,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
577,625169,1,6,,103275455,1057,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
578,625170,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
579,625171,4,7,,103275455,1057,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
580,625172,4,7,,103275455,1057,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
581,625173,5,5,,103275455,1057,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
582,625174,5,5,,103275455,1057,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
583,625175,5,5,,103275455,1057,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
584,625176,1,9,,103275455,1057,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
585,625177,5,5,,103275455,1057,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
586,625178,5,5,,103275455,1057,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
587,625179,1,9,,103275455,1057,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
588,625180,5,5,,103275455,1057,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
589,625181,5,5,,103275455,1057,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
590,625182,5,5,,103275455,1057,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
591,625183,5,5,,103275455,1057,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
592,625184,5,5,,103275455,1057,Active,2811086.0,1956.0,1.23,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
593,625185,5,5,,103275455,1057,Active,125370.0,2534.0,0.997,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
594,625186,5,5,,103275455,1057,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
595,625187,5,5,,103275455,1057,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
596,625188,1,9,,103275455,1057,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
597,625189,1,7,,103275455,1057,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
598,625190,4,5,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
599,625191,4,7,,103275455,1057,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
600,625192,4,7,,103275455,1057,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
601,625193,5,5,,103275455,1057,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
602,625194,4,7,,103275455,1057,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
603,625195,4,7,,103275455,1057,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
604,625196,5,6,,103275455,1057,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
605,625197,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
606,625198,4,7,,103275455,1057,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
607,625199,4,7,,103275455,1057,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
608,625200,4,7,,103275455,1057,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
609,625201,4,7,,103275455,1057,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
610,625202,4,7,,103275455,1057,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
611,625203,4,7,,103275455,1057,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
612,625204,4,7,,103275455,1057,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
613,625205,4,7,,103275455,1057,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
614,625206,4,7,,103275455,1057,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
615,625207,4,7,,103275455,1057,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
616,625208,5,5,,103275455,1057,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
617,625209,4,7,,103275455,1057,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
618,625210,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
619,625211,1,6,,103275455,1057,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
620,625212,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
621,625213,4,7,,103275455,1057,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
622,625214,1,9,,103275455,1057,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
623,625215,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
624,625216,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
625,625217,4,7,,103275455,1057,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
626,625218,4,7,,103275455,1057,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
627,625219,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
628,625220,4,7,,103275455,1057,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
629,625221,4,7,,103275455,1057,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
630,625222,4,7,,103275455,1057,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
631,625223,4,7,,103275455,1057,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
632,625224,3,4,,103275455,1057,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
633,625225,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
634,625226,4,7,,103275455,1057,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
635,625227,4,7,,103275455,1057,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
636,625228,4,7,,103275455,1057,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
637,625229,5,5,,103275455,1057,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
638,625230,1,6,,103275455,1057,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
639,625231,4,7,,103275455,1057,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
640,625232,1,9,,103275455,1057,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
641,625233,4,7,,103275455,1057,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
642,625234,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
643,625235,4,7,,103275455,1057,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
644,625236,5,5,,103275455,1057,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
645,625237,4,7,,103275455,1057,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
646,625238,4,7,,103275455,1057,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
647,625239,4,7,,103275455,1057,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
648,625240,1,9,,103275455,1057,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
649,625241,4,7,,103275455,1057,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
650,625242,4,7,,103275455,1057,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
651,625243,5,5,,103275455,1057,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
652,625244,5,5,,103275455,1057,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
653,625245,5,5,,103275455,1057,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
654,625246,1,9,,103275455,1057,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
655,625247,5,5,,103275455,1057,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
656,625248,5,5,,103275455,1057,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
657,625249,5,5,,103275455,1057,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
658,625250,5,5,,103275455,1057,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
659,625251,5,5,,103275455,1057,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
660,625252,4,7,,103275455,1057,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
661,625253,4,7,,103275455,1057,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
662,625254,4,7,,103275455,1057,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
663,625255,4,7,,103275455,1057,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
664,625256,4,7,,103275455,1057,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
665,625257,4,7,,103275455,1057,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
666,625258,4,7,,103275455,1057,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
667,625259,4,7,,103275455,1057,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
668,625260,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
669,625261,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
670,625262,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
671,625263,4,7,,103275455,1057,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
672,625264,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
673,625265,1,6,,103275455,1057,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
674,625266,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
675,625267,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
676,625268,4,2,,103275455,1057,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
677,625268,4,2,,103275455,1057,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
678,625268,4,2,,103275455,1057,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
679,625268,4,2,,103275455,1057,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
680,625269,4,7,,103275455,1057,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
681,625270,4,7,,103275455,1057,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
682,625271,5,5,,103275455,1057,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
683,625272,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
684,625273,4,6,,103275455,1057,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
685,625274,1,6,,103275455,1057,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
686,625275,3,4,,103275455,1057,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
687,651631,4,1,,144204694,1057,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
688,651631,4,1,,144209571,1057,Inconclusive,269849759.0,7157.0,60.5715,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
689,651632,4,1,,144204694,1057,Inconclusive,296439460.0,79915.0,13.3332,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
690,651632,4,1,,144209571,1057,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
691,651633,4,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
692,651633,4,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
693,651634,4,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
694,651634,4,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
695,651741,1,1,,17388747,1057,Active,20149576.0,4780.0,5.9557,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
696,651743,1,1,,17388747,1057,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
697,651749,1,1,,17388747,1057,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
698,651751,1,1,,17388747,1057,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
699,651754,1,1,,17388747,1057,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
700,651755,1,1,,17388747,1057,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
701,651757,1,1,,17388747,1057,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
702,651758,1,1,,17388747,1057,Active,186368.0,3576.0,74.97800000000001,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
703,651777,1,1,,17388747,1057,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
704,651778,1,1,,17388747,1057,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
705,651802,1,1,,17388747,1057,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
706,651838,1,1,,17388747,1057,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
707,651838,1,1,1.0,17388747,1057,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
708,651838,1,1,2.0,17388747,1057,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
709,651838,1,1,3.0,17388747,1057,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
710,651838,1,1,4.0,17388747,1057,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
711,651838,1,1,5.0,17388747,1057,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
712,651838,1,1,6.0,17388747,1057,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
713,651838,1,1,7.0,17388747,1057,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
714,651838,1,1,8.0,17388747,1057,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
715,652048,1,2,,144204694,1057,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
716,652051,1,1,,144204694,1057,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
717,686978,1,1,,144204694,1057,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
718,686979,1,1,,144204694,1057,Active,79154014.0,55775.0,5.9569,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
719,720516,2,1,,144204694,1057,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
720,720516,2,1,,144209571,1057,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
721,720532,1,1,,144204694,1057,Inconclusive,420597.0,,31.6228,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
722,720533,1,1,,144204694,1057,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
723,720552,2,1,,144204694,1057,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
724,720552,2,1,,144209571,1057,Active,269849759.0,7157.0,65.4036,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
725,720634,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
726,720634,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
727,720635,2,1,,144204694,1057,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
728,720635,2,1,,144209571,1057,Inconclusive,,,0.4811,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
729,720636,1,1,,17388747,1057,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
730,720637,2,1,,144204694,1057,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
731,720637,2,1,,144209571,1057,Active,,,12.0856,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
732,720652,1,1,,17388747,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
733,720653,1,1,,17388747,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
734,720659,1,1,,17388747,1057,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
735,720674,2,2,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
736,720674,2,2,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
737,720675,2,2,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
738,720675,2,2,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
739,720678,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
740,720678,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
741,720679,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
742,720679,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
743,720680,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
744,720680,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
745,720681,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
746,720681,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
747,720682,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
748,720682,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
749,720683,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
750,720683,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
751,720684,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
752,720684,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
753,720685,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
754,720685,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
755,720686,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
756,720686,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
757,720687,2,2,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
758,720687,2,2,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
759,720691,4,1,,144204694,1057,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
760,720691,4,1,,144209571,1057,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
761,720692,3,1,,144204694,1057,Inconclusive,311348376.0,2908.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
762,720692,3,1,,144209571,1057,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
763,720693,3,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
764,720693,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
765,720719,2,1,,144204694,1057,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
766,720719,2,1,,144209571,1057,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
767,720725,2,1,,144204694,1057,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
768,720725,2,1,,144209571,1057,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
769,733601,1,6,,103275455,1057,Unspecified,401235.0,7299.0,,,Inactivation of tyrosinase (unknown origin) assessed as total oxygen uptake using 4-methylcatechol substrate at 850 uM equimolar concentrations resorcinol by spectrophotometry,Other,23352755.0,
770,733603,1,6,,103275455,1057,Unspecified,401235.0,7299.0,,,Inactivation of tyrosinase (unknown origin) assessed as initial rate of oxygen utilization at absorbance 400 nm using 4-methylcatechol substrate at 850 uM equimolar concentrations resorcinol by spectrophotometry,Other,23352755.0,
771,733605,1,6,,103275455,1057,Unspecified,401235.0,7299.0,,,Inactivation of tyrosinase (unknown origin) assessed as initial rate of oxygen utilization using 4-methylcatechol substrate at 850 uM equimolar concentrations resorcinol by spectrophotometry,Other,23352755.0,
772,743012,3,1,,144204694,1057,Active,,,26.6032,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
773,743012,3,1,,144209571,1057,Inconclusive,,,67.9623,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
774,743014,3,1,,144204694,1057,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
775,743014,3,1,,144209571,1057,Active,,,48.1136,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
776,743015,3,1,,144204694,1057,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
777,743015,3,1,,144209571,1057,Inconclusive,,,67.9623,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
778,743033,3,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
779,743033,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
780,743035,2,1,,144204694,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
781,743035,2,1,,144209571,1057,Inconclusive,124375976.0,367.0,19.327,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
782,743036,2,1,,144204694,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
783,743036,2,1,,144209571,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
784,743040,3,1,,144204694,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
785,743040,3,1,,144209571,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
786,743041,3,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
787,743041,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
788,743042,3,1,,144204694,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
789,743042,3,1,,144209571,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
790,743053,2,1,,144204694,1057,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
791,743053,2,1,,144209571,1057,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
792,743054,2,1,,144204694,1057,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
793,743054,2,1,,144209571,1057,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
794,743063,2,1,,144204694,1057,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
795,743063,2,1,,144209571,1057,Inconclusive,124375976.0,367.0,19.327,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
796,743064,3,1,,144204694,1057,Inconclusive,,,0.0094,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
797,743064,3,1,,144209571,1057,Inconclusive,,,27.0563,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
798,743065,3,1,,144204694,1057,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
799,743065,3,1,,144209571,1057,Inactive,399498506.0,24831.0,24.1139,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
800,743066,3,1,,144204694,1057,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
801,743066,3,1,,144209571,1057,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
802,743067,2,1,,144204694,1057,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
803,743067,2,1,,144209571,1057,Inconclusive,399498506.0,24831.0,24.1139,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
804,743069,2,1,,144204694,1057,Inconclusive,348019627.0,2099.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
805,743069,2,1,,144209571,1057,Inconclusive,348019627.0,2099.0,8.633,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
806,743074,2,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
807,743074,2,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
808,743075,2,1,,144204694,1057,Active,348019627.0,2099.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
809,743075,2,1,,144209571,1057,Active,348019627.0,2099.0,54.4708,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
810,743077,2,1,,144204694,1057,Active,348019627.0,2099.0,24.8257,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
811,743077,2,1,,144209571,1057,Active,348019627.0,2099.0,45.8371,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
812,743078,2,1,,144204694,1057,Inconclusive,348019627.0,2099.0,23.9145,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
813,743078,2,1,,144209571,1057,Inconclusive,348019627.0,2099.0,15.9526,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
814,743079,3,1,,144204694,1057,Active,348019627.0,2099.0,5.9557,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
815,743079,3,1,,144209571,1057,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
816,743080,3,1,,144204694,1057,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
817,743080,3,1,,144209571,1057,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
818,743081,3,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
819,743081,3,1,,144209571,1057,Inconclusive,,,67.9623,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
820,743083,3,1,,144204694,1057,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
821,743083,3,1,,144209571,1057,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
822,743084,3,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
823,743084,3,1,,144209571,1057,Inconclusive,,,53.9844,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
824,743085,3,1,,144204694,1057,Inconclusive,51095037.0,196.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
825,743085,3,1,,144209571,1057,Inconclusive,51095037.0,196.0,24.1139,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
826,743086,3,1,,144204694,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
827,743086,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
828,743091,2,1,,144204694,1057,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
829,743091,2,1,,144209571,1057,Inconclusive,348019627.0,2099.0,32.1565,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
830,743094,3,1,,144204694,1057,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
831,743094,3,1,,144209571,1057,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
832,743122,2,1,,144204694,1057,Inconclusive,51095037.0,196.0,18.8336,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
833,743122,2,1,,144209571,1057,Active,51095037.0,196.0,42.8813,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
834,743139,2,1,,144204694,1057,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
835,743139,2,1,,144209571,1057,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
836,743140,2,1,,144204694,1057,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
837,743140,2,1,,144209571,1057,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
838,743191,3,1,,144209571,1057,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
839,743194,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
840,743199,2,1,,144209571,1057,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
841,743202,4,1,,144209571,1057,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
842,743203,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
843,743209,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
844,743210,4,1,,144209571,1057,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
845,743211,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
846,743212,3,1,,144209571,1057,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
847,743213,3,1,,144209571,1057,Inconclusive,,,0.0306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
848,743215,3,1,,144209571,1057,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
849,743217,3,1,,144209571,1057,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
850,743218,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
851,743219,3,1,,144209571,1057,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
852,743220,3,1,,144209571,1057,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
853,743221,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
854,743222,3,1,,144209571,1057,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
855,743223,3,1,,144209571,1057,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
856,743224,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
857,743225,3,1,,144209571,1057,Inconclusive,,,0.1933,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
858,743226,2,1,,144209571,1057,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
859,743227,2,1,,144209571,1057,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
860,743228,3,1,,144209571,1057,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
861,743239,2,1,,144209571,1057,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
862,743240,2,1,,144209571,1057,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
863,743241,2,1,,144209571,1057,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
864,743242,2,1,,144209571,1057,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
865,743244,1,1,,144204694,1057,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
866,743288,1,1,,17388747,1057,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
867,743292,1,1,,17388747,1057,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
868,943721,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020924,Other,,
869,943722,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020924,Other,,
870,943723,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020924,Other,,
871,943724,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020924,Other,,
872,943725,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020924,Other,,
873,943726,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020924,Other,,
874,943727,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020924,Other,,
875,943728,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020924,Other,,
876,943729,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020924,Other,,
877,943730,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020924,Other,,
878,943731,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020924,Other,,
879,943732,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020924,Other,,
880,943733,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020924,Other,,
881,947294,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020924,Other,,
882,947295,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020924,Other,,
883,947296,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020924,Other,,
884,947297,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020924,Other,,
885,947298,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020924,Other,,
886,947299,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020924,Other,,
887,947300,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020924,Other,,
888,947301,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020924,Other,,
889,947302,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020924,Other,,
890,947303,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020924,Other,,
891,947304,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020924,Other,,
892,947305,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020924,Other,,
893,947306,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020924,Other,,
894,965166,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020924,Other,,
895,965167,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020924,Other,,
896,965168,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020924,Other,,
897,965169,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020924,Other,,
898,965170,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020924,Other,,
899,965171,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020924,Other,,
900,965172,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020924,Other,,
901,965173,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020924,Other,,
902,965174,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020924,Other,,
903,965175,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020924,Other,,
904,965176,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020924,Other,,
905,965177,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020924,Other,,
906,965178,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020924,Other,,
907,965179,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020924,Other,,
908,965180,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020924,Other,,
909,967390,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020924,Other,,
910,967391,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020924,Other,,
911,977460,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020924,Other,,
912,977461,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020924,Other,,
913,977462,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020924,Other,,
914,977463,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020924,Other,,
915,977464,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020924,Other,,
916,977465,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020924,Other,,
917,977466,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020924,Other,,
918,977467,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020924,Other,,
919,977468,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020924,Other,,
920,977469,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020924,Other,,
921,977470,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020924,Other,,
922,977471,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020924,Other,,
923,977472,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020924,Other,,
924,1029524,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R020924",Other,,
925,1029525,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R020924",Other,,
926,1029526,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R020924",Other,,
927,1029527,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R020924",Other,,
928,1029528,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020924",Other,,
929,1029529,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020924",Other,,
930,1030112,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R020924,Other,,
931,1030113,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R020924",Other,,
932,1030114,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R020924,Other,,
933,1030115,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R020924",Other,,
934,1030116,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R020924",Other,,
935,1030117,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R020924",Other,,
936,1030118,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R020924",Other,,
937,1030119,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R020924",Other,,
938,1030120,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R020924",Other,,
939,1030121,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R020924",Other,,
940,1030122,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020924",Other,,
941,1030123,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020924",Other,,
942,1030124,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020924",Other,,
943,1030125,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R020924",Other,,
944,1030126,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R020924",Other,,
945,1030127,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020924",Other,,
946,1030128,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R020924",Other,,
947,1030129,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R020924",Other,,
948,1030130,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R020924",Other,,
949,1030131,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R020924",Other,,
950,1030132,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R020924",Other,,
951,1030133,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R020924",Other,,
952,1030134,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R020924",Other,,
953,1030135,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R020924,Other,,
954,1030136,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R020924,Other,,
955,1030137,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R020924",Other,,
956,1032004,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020924",Other,,
957,1032005,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R020924",Other,,
958,1032006,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R020924",Other,,
959,1032007,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R020924,Other,,
960,1032008,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020924",Other,,
961,1032009,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R020924",Other,,
962,1032010,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R020924",Other,,
963,1032011,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R020924",Other,,
964,1032012,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R020924,Other,,
965,1032598,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020924",Other,,
966,1032599,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R020924",Other,,
967,1032600,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R020924",Other,,
968,1032601,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R020924",Other,,
969,1032602,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R020924",Other,,
970,1032603,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R020924",Other,,
971,1032604,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R020924",Other,,
972,1032605,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R020924,Other,,
973,1032606,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R020924",Other,,
974,1032607,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R020924",Other,,
975,1032608,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R020924",Other,,
976,1032609,1,3,,103275455,1057,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R020924,Other,,
977,1032610,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R020924",Other,,
978,1032611,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R020924",Other,,
979,1032612,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R020924",Other,,
980,1032613,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R020924",Other,,
981,1032614,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R020924",Other,,
982,1032615,1,3,,103275455,1057,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R020924",Other,,
983,1117326,1,1,,225144211,1057,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
984,1117329,1,1,,225144211,1057,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
985,1117336,1,1,,225144211,1057,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
986,1117340,1,1,,225144211,1057,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
987,1117341,1,1,,225144211,1057,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
988,1117342,1,1,,225144211,1057,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
989,1117343,1,1,,225144211,1057,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
990,1117346,1,1,,225144211,1057,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
991,1159509,1,1,,144209571,1057,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
992,1159515,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
993,1159516,1,1,,144209571,1057,Inconclusive,119611100.0,22926.0,54.4708,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
994,1159517,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
995,1159518,1,1,,144209571,1057,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
996,1159519,1,1,,144209571,1057,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
997,1159520,1,1,,144209571,1057,Inconclusive,,,53.9844,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
998,1159521,1,1,,144209571,1057,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
999,1159523,1,1,,144209571,1057,Inconclusive,15928672.0,19885.0,20.2894,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1000,1159525,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1001,1159526,1,1,,144209571,1057,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1002,1159527,1,1,,144209571,1057,Inconclusive,325495497.0,6256.0,10.8684,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1003,1159528,1,1,,144209571,1057,Inconclusive,119627033.0,3725.0,38.5624,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1004,1159529,1,1,,144209571,1057,Inconclusive,,,54.4708,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1005,1159531,1,1,,144209571,1057,Active,325495497.0,6256.0,12.1945,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1006,1159551,1,1,,144209571,1057,Inconclusive,,,60.5715,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1007,1159552,1,1,,144209571,1057,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1008,1159553,2,1,,144209571,1057,Active,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1009,1159555,1,1,,144209571,1057,Inconclusive,325495463.0,5914.0,60.5715,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1010,1224834,3,1,,144209571,1057,Inconclusive,,,60.5715,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1011,1224835,1,1,,144209571,1057,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1012,1224836,1,1,,144209571,1057,Inconclusive,,,67.9623,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1013,1224837,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1014,1224838,1,1,,144209571,1057,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1015,1224839,1,1,,144209571,1057,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1016,1224840,3,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1017,1224841,3,1,,144209571,1057,Inactive,325495545.0,2101.0,8.556000000000001,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1018,1224842,3,1,,144209571,1057,Active,325495545.0,2101.0,8.556000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1019,1224843,1,1,,144209571,1057,Inconclusive,119601739.0,7253.0,48.1136,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1020,1224844,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1021,1224845,1,1,,144209571,1057,Inconclusive,344243002.0,100757539.0,56.1534,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1022,1224846,1,1,,144209571,1057,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1023,1224847,1,1,,144209571,1057,Inconclusive,,,99.8564,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1024,1224848,3,1,,144209571,1057,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1025,1224849,3,1,,144209571,1057,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1026,1224867,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1027,1224868,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1028,1224869,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1029,1224870,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1030,1224871,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1031,1224872,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1032,1224873,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1033,1224874,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1034,1224875,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1035,1224876,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1036,1224877,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1037,1224878,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1038,1224879,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1039,1224880,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1040,1224881,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1041,1224882,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1042,1224883,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1043,1224884,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1044,1224885,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1045,1224886,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1046,1224887,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1047,1224888,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1048,1224889,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1049,1224890,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1050,1224892,1,1,,144209571,1057,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1051,1224893,1,1,,144209571,1057,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1052,1224894,1,1,,144209571,1057,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1053,1224895,1,1,,144209571,1057,Active,119601739.0,7253.0,30.3577,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1054,1224896,1,1,,144209571,1057,Active,344243002.0,100757539.0,56.1534,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1055,1259241,1,1,,144209571,1057,Inconclusive,,,60.5715,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1056,1259242,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1057,1259243,1,1,,144209571,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1058,1259244,1,1,,144209571,1057,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1059,1259247,1,1,,144209571,1057,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1060,1259248,1,1,,144209571,1057,Inconclusive,348019627.0,2099.0,25.5428,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1061,1259344,1,1,,144204694,1057,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1062,1259355,1,1,,144204694,1057,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1063,1259356,1,1,,144204694,1057,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1064,1259364,1,1,,144209571,1057,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1065,1259365,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1066,1259366,1,1,,144209571,1057,Inconclusive,,,60.5715,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1067,1259367,1,1,,144209571,1057,Active,,,48.1136,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1068,1259368,1,1,,144209571,1057,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1069,1259369,1,1,,144209571,1057,Active,109731339.0,2737.0,15.2149,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1070,1259377,1,1,,144209571,1057,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1071,1259378,1,1,,144209571,1057,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1072,1259379,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1073,1259380,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1074,1259381,1,1,,144209571,1057,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1075,1259382,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1076,1259383,1,1,,144209571,1057,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1077,1259384,1,1,,144209571,1057,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1078,1259385,1,1,,144209571,1057,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1079,1259386,1,1,,144209571,1057,Active,,,67.9623,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1080,1259387,1,1,,144209571,1057,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1081,1259388,1,1,,144209571,1057,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1082,1259390,1,1,,144209571,1057,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1083,1259391,1,1,,144209571,1057,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1084,1259392,1,1,,144209571,1057,Inconclusive,109731339.0,2737.0,24.1139,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1085,1259393,1,1,,144209571,1057,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1086,1259394,1,1,,144209571,1057,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1087,1259395,1,1,,144209571,1057,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1088,1259396,1,1,,144209571,1057,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1089,1259401,1,1,,144209571,1057,Inconclusive,325495545.0,2101.0,10.3658,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1090,1259402,1,1,,144209571,1057,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1091,1259403,1,1,,144209571,1057,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1092,1259404,1,1,,144209571,1057,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1093,1259407,1,1,,363899890,1057,Active,,,,,CCRIS mutagenicity studies,Other,,
1094,1259408,1,1,,363895109,1057,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1095,1259409,1,1,,363899890,1057,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
